Subchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome

Journal of Pharmacology and Experimental Therapeutics

Volumn 338, Issue 3, 2011, Pages 897-905

  Pacey, Laura K K ^a   Tharmalingam, Sujeenthar ^a   Hampson, David R ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 CYANO N (1,3 DIPHENYL 1H PYRAZOL 5 YL)BENZAMIDE; 4 AMINOBUTYRIC ACID B RECEPTOR; ANTICONVULSIVE AGENT; BACLOFEN; METABOTROPIC RECEPTOR; N,N' DICYCLOPENTYL 2 METHYLTHIO 5 NITRO 4,6 PYRIMIDINEDIAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; AUDIOGENIC SEIZURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERANCE; FRAGILE X SYNDROME; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE;

ANIMALS; ANTICONVULSANTS; BACLOFEN; BENZAMIDES; BLOTTING, WESTERN; CYCLOPENTANES; DRUG INTERACTIONS; DRUG TOLERANCE; EPILEPSY, REFLEX; EXCITATORY AMINO ACID ANTAGONISTS; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; GABA AGONISTS; GABA MODULATORS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PYRAZOLES; PYRIDINES; PYRIMIDINES; RECEPTORS, GABA-B; RECEPTORS, KAINIC ACID; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 80052166631     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.183327     Document Type: Article

References (39)

1. Adusei DC, Pacey LK, Chen D, and Hampson DR (2010) Early developmental alterations in GABAergic protein expression in fragile X knockout mice. Neuropharmacology 59:167-171.
2. Akman MN, Loubser PG, Donovan WH, O'Neill ME, and Rossi CD (1993) Intrathecal baclofen: does tolerance occur? Paraplegia 31:516-520. (Pubitemid 23264687)
3. Bear MF (2005) Therapeutic implications of the mGluR theory of fragile X mental retardation. Genes Brain Behav 4:393-398.
4. Bear MF, Huber KM, and Warren ST (2004) The mGluR theory of fragile X mental retardation. Trends Neurosci 27:370-377. (Pubitemid 38829251)
5. Chang S, Bray SM, Li Z, Zarnescu DC, He C, Jin P, and Warren ST (2008) Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. Nat Chem Biol 4:256-263. (Pubitemid 351419125)
6. Chen L and Toth M. (2001) Fragile X mice develop sensory hyperreactivity to auditory stimuli. Neuroscience 103:1043-1050. (Pubitemid 32289314)
7. Chen Y, Nong Y, Goudet C, Hemstapat K, de Paulis T, Pin JP, and Conn PJ (2007) Interaction of novel positive allosteric modulators of metabotropic glutamate receptor 5 with the negative allosteric antagonist site is required for potentiation of receptor responses. Mol Pharmacol 71:1389-1398. (Pubitemid 46661543)
8. Cowen MS, Djouma E, and Lawrence AJ (2005) The metabotropic glutamate 5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine reduces ethanol self-administration in multiple strains of alcohol-preferring rats and regulates olfactory glutamatergic systems. J Pharmacol Exp Ther 315:590-600.
9. Cryan JF, Kelly PH, Chaperon F, Gentsch C, Mombereau C, Lingenhoehl K, Froestl W, Bettler B, Kaupmann K, and Spooren WP (2004) Behavioral characterization of the novel GABAB receptor-positive modulator GS39783 (N,N′-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine): anxiolytic-like activity without side effects associated with baclofen or benzodiazepines. J Pharmacol Exp Ther 310:952-963. (Pubitemid 39108915)
10. Curia G, Papouin T, Séguéla P, and Avoli M (2009) Downregulation of tonic GABAergic inhibition in a mouse model of fragile X syndrome. Cereb Cortex 19:1515-1520.
11. D'Hulst C, De Geest N, Reeve SP, Van Dam D, De Deyn PP, Hassan BA, and Kooy RF (2006) Decreased expression of the GABAA receptor in fragile X syndrome. Brain Res 1121:238-245. (Pubitemid 44708899)
12. D'Hulst C, Heulens I, Brouwer JR, Willemsen R, De Geest N, Reeve SP, De Deyn PP, Hassan BA, and Kooy RF (2009) Expression of the GABAergic system in animal models for fragile X syndrome and fragile X associated tremor/ataxia syndrome (FXTAS). Brain Res 1253:176-183.
13. de Vrij FM, Levenga J, Van der Linde HC, Koekkoek SK, De Zeeuw CI, Nelson DL, Oostra BA, and Willemsen R (2008) Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol Dis 31:127-132. (Pubitemid 351822560)
14. Dölen G, Osterweil E, Rao BS, Smith GB, Auerbach BD, Chattarji S, and Bear MF (2007) Correction of fragile X syndrome in mice. Neuron 56:955-962. (Pubitemid 350251119)
15. El Idrissi A, Ding XH, Scalia J, Trenkner E, Brown WT, and Dobkin C (2005) Decreased GABA(A) receptor expression in the seizure-prone fragile X mouse. Neurosci Lett 377:141-146. (Pubitemid 40332346)
16. Fatemi SH, Folsom TD, Reutiman TJ, and Thuras PD (2009) Expression of GABA(B) receptors is altered in brains of subjects with autism. Cerebellum 8:64-69.
17. Gasparini F, Bilbe G, Gomez-Mancilla B, and Spooren W (2008) mGluR5 antagonists: discovery, characterization and drug development. Curr Opin Drug Discov Devel 11:655-665.
18. Gjoni T and Urwyler S (2008) Receptor activation involving positive allosteric modulation, unlike full agonism, does not result in GABAB receptor desensitization. Neuropharmacology 55:1293-1299.
19. Gregory KJ, Dong EN, Meiler J, and Conn PJ (2011) Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential. Neuropharmacology 60:66-81.
20. Hampson DR, Adusei DC, and Pacey LK (2011) The neurochemical basis for the treatment of autism spectrum disorders and fragile X syndrome. Biochem Pharmacol 81:1078-1086.
21. Keov P, Sexton PM, and Christopoulos A (2011) Allosteric modulation of G proteincoupled receptors: a pharmacological perspective. Neuropharmacology 60:24-35.
22. Kinney GG, O'Brien JA, Lemaire W, Burno M, Bickel DJ, Clements MK, Chen TB, Wisnoski DD, Lindsley CW, Tiller PR, et al. (2005) A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J Pharmacol Exp Ther 313:199-206. (Pubitemid 40411343)
23. Lehmann A, Mattsson JP, Edlund A, Johansson T, and Ekstrand AJ (2003) Effects of repeated administration of baclofen to rats on GABAB receptor binding sites and subunit expression in the brain. Neurochem Res 28:387-393. (Pubitemid 36207364)
24. Levenga J, De Vrij FM, Oostra BA, and Willemsen R (2010) Potential therapeutic interventions for fragile X syndrome. Trends Mol Med 16:516-527.
25. McBride SM, Choi CH, Wang Y, Liebelt D, Braunstein E, Ferreiro D, Sehgal A, Siwicki KK, Dockendorff TC, Nguyen HT, et al. (2005) Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron 45:753-764. (Pubitemid 40320709)
26. Mombereau C, Kaupmann K, Froestl W, Sansig G, van der Putten H, and Cryan JF (2004) Genetic and pharmacological evidence of a role for GABA(B) receptors in the modulation of anxiety- and antidepressant-like behavior. Neuropsychopharmacology 29:1050-1062. (Pubitemid 38670043)
27. Musumeci SA, Bosco P, Calabrese G, Bakker C, De Sarro GB, Elia M, Ferri R, and Oostra BA (2000) Audiogenic seizures susceptibility in transgenic mice with fragile X syndrome. Epilepsia 41:19-23. (Pubitemid 30036849)
28. Nielsen JF, Hansen HJ, Sunde N, and Christensen JJ (2002) Evidence of tolerance to baclofen in treatment of severe spasticity with intrathecal baclofen. Clin Neurol Neurosurg 104:142-145. (Pubitemid 34262654)
29. Olmos-Serrano JL, Paluszkiewicz SM, Martin BS, Kaufmann WE, Corbin JG, and Huntsman MM (2010) Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome. J Neurosci 30:9929-9938.
30. Pacey LK, Doss L, Cifelli C, van der Kooy D, Heximer SP, and Hampson DR (2011) Genetic deletion of regulator of G-protein signaling 4 (RGS4) rescues a subset of fragile X related phenotypes in the FMR1 knockout mouse. Mol Cell Neurosci 46:563-572.
31. Pacey LK, Heximer SP, and Hampson DR (2009) Increased GABA(B) receptor-mediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures. Mol Pharmacol 76:18-24.
32. Parmentier-Batteur S, Obrien JA, Doran S, Nguyen SJ, Flick RB, Uslaner JM, Chen H, Finger EN, Williams TM, Jacobson MA, et al. (2010) Differential effects of the mGluR5 positive allosteric modulator CDPPB in the cortex and striatum following repeated administration. Neuropharmacology doi:10.1016/j.neuropharm.2010.11.013.
33. Rives ML, Vol C, Fukazawa Y, Tinel N, Trinquet E, Ayoub MA, Shigemoto R, Pin JP, and Prézeau L (2009) Crosstalk between GABAB and mGlu1a receptors reveals new insight into GPCR signal integration. EMBO J 28:2195-2208.
34. Rodriguez AL, Grier MD, Jones CK, Herman EJ, Kane AS, Smith RL, Williams R, Zhou Y, Marlo JE, Days EL, et al. (2010) Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Mol Pharmacol 78:1105-1123.
35. Sands SA, McCarson KE, and Enna SJ (2003) Differential regulation of GABA B receptor subunit expression and function. J Pharmacol Exp Ther 305:191-196. (Pubitemid 36373850)
36. Uslaner JM, Parmentier-Batteur S, Flick RB, Surles NO, Lam JS, McNaughton CH, Jacobson MA, and Hutson PH (2009) Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus. Neuropharmacology 57:531-538.
37. Vigot R, Barbieri S, Bräuner-Osborne H, Turecek R, Shigemoto R, Zhang YP, Luján R, Jacobson LH, Biermann B, Fritschy JM, et al. (2006) Differential compartmentalization and distinct functions of GABAB receptor variants. Neuron 50:589-601.
38. Yan QJ, Rammal M, Tranfaglia M, and Bauchwitz RP (2005) Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 49:1053-1066. (Pubitemid 41503304)
39. Zupan B and Toth M (2008) Inactivation of the maternal fragile X gene results in sensitization of GABAB receptor function in the offspring. J Pharmacol Exp Ther 327:820-826.